1477-86-7

Usage

Uses

Used in Organic Synthesis:
Benzenamine, 5-chloro-N-(4-fluorophenyl)-2-nitro-, is utilized as a building block in organic synthesis for the creation of a variety of bioactive molecules. Its unique structure allows for the development of new compounds with potential applications in various fields.
Used in Pharmaceutical Research:
In pharmaceutical research, Benzenamine, 5-chloro-N-(4-fluorophenyl)-2-nitro- serves as an intermediate for the synthesis of pharmaceutical drugs. Its presence of both chloro and nitro substitutions, along with the 4-fluorophenyl group, makes it a valuable component in the design and synthesis of new medicinal agents.
Used in Agrochemical Production:
Benzenamine, 5-chloro-N-(4-fluorophenyl)-2-nitro-, is also employed as an intermediate in the production of agrochemicals. Its chemical properties contribute to the development of effective products for agricultural applications.
Used in Dye Manufacturing:
Benzenamine, 5-chloro-N-(4-fluorophenyl)-2-nitrois used in the manufacturing of dyes due to its chemical structure that can impart color. Its role in dye production is significant for creating dyes with specific properties for various industrial uses.
Safety Considerations:
Due to the presence of nitro and chloro substitutions, Benzenamine, 5-chloro-N-(4-fluorophenyl)-2-nitro-, requires careful handling and adherence to proper safety protocols when used in a laboratory setting. This is to ensure the safety of personnel and to prevent any potential hazards associated with the compound.

Upstream product

• 610-40-2 3,4-dinitro-chlorobenzene 
• 371-40-4 4-fluoroaniline 
• 611-06-3 2,4-dichloronitrobenzene 

Downstream Products

• 958264-00-1 8-chloro-10-(4-fluorophenyl)-10H-benzo[g]pteridine-2,4-dione 
• 958263-95-1 3-(3-dimethylaminopropyl)-8-(3-dimethylaminopropylamino)-10-(4-fluorophenyl)-10H-benzo[g]pteridine-2,4-dione 
• 958264-06-7 8-chloro-3-(3-dimethylaminopropyl)-10-(4-fluorophenyl)-10H-benzo[g]pteridine-2,4-dione 
• 1693-23-8 (5-Methoxy-2-nitrophenyl)-(4-fluorophenyl)amine 

Relevant academic research and scientific papers

10H-BENZO(G)PTERDINE-2,4-DIONE COMPOUNDS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

This invention pertains generally to the field of G-quadruplex ligands, and more particularly, to certain 10H-benzo[g]pteridine-2,4-dione compounds ("BPD compounds"), as described herein, which, inter alia, (selectively) bind (and stabilize) G-quadruplexes. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to (selectively) bind (and stabilize) G-quadruplexes, to inhibit telomerase, to regulate cell proliferation, and in the treatment of proliferative disorders, such as cancer. Formula (I):

Trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands: Small molecule regulation of c-kit oncogene expression

Herein, we report the design, synthesis, biophysical evaluation with primary biological data of 3,8,10-trisubstituted isoalloxazines as a new class of G-quadruplex binding ligands. We have developed a short and robust synthesis for trisubstituted isoalloxazines in good yields. The G-quadruplex binding and stabilization potential of isoalloxazines was assessed by surface plasmon resonance and fluorescence resonance energy transfer assay. The data revealed that these isoalloxazines bind and stabilize G-quadruplex DNA, but not duplex DNA, and exhibit potential for discriminating between DNA quadruplexes. Cell-based experiments using cell lines that express the proto-oncogene c-kit (MCF-7 and HGC-27) showed that such isoalloxazines can inhibit the expression of c-kit. Copyright

1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives

New benzimidazole derivatives are described, their production and their use for the production of pharmaceutical agents for treatment and prevention of diseases that are associated with a microglia activation and T-cell-mediated immunological diseases, as